A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis.

Gül, Ceren; Gül, Aytül; Karakavuk, Tugba; Erkunt Alak, Sedef; Karakavuk, Muhammet; Can, Hüseyin; Degirmenci Döskaya, Aysu; Yavuz, Irem; Kaplan, Seren; Erel Akbaba, Gülsah; Sen Karaman, Didem; Akbaba, Hasan; Efe Köseoglu, Ahmet; Ovayurt, Tolga; Yüksel Gürüz, Adnan; Ün, Cemal; Kantarci, Ayse Gülten; Döskaya, Mert

Gül, Ceren; Gül, Aytül; Karakavuk, Tugba; Erkunt Alak, Sedef; Karakavuk, Muhammet; Can, Hüseyin; Degirmenci Döskaya, Aysu; Yavuz, Irem; Kaplan, Seren; Erel Akbaba, Gülsah; Sen Karaman, Didem; Akbaba, Hasan; Efe Köseoglu, Ahmet; Ovayurt, Tolga; Yüksel Gürüz, Adnan; Ün, Cemal; Kantarci, Ayse Gülten; Döskaya, Mert.

Afiliación

Gül C; Ege University, Graduate School of Natural and Applied Sciences, Department of Biotechnology, Izmir, Türkiye; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye.
Gül A; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Faculty of Engineering, Department of Bioengineering, Izmir, Türkiye.
Karakavuk T; Ege University, Graduate School of Natural and Applied Sciences, Department of Biotechnology, Izmir, Türkiye; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye.
Erkunt Alak S; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Faculty of Science, Department of Biology Molecular Biology Section, Izmir, Türkiye.
Karakavuk M; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Ödemis Vocational School, Izmir, Türkiye; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye.
Can H; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Faculty of Science, Department of Biology Molecular Biology Section, Izmir, Türkiye; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye.
Degirmenci Döskaya A; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye; Ege University, Faculty of Medicine, Department of Parasitology, Izmir, Türkiye.
Yavuz I; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye.
Kaplan S; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye.
Erel Akbaba G; Izmir Katip Çelebi University, Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Izmir, Türkiye.
Sen Karaman D; Izmir Katip Çelebi University, Faculty of Engineering and Architecture, Department of Biomedical Engineering, Izmir, Türkiye.
Akbaba H; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye; Ege University, Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Izmir, Türkiye.
Efe Köseoglu A; Ege University, Faculty of Science, Department of Biology Molecular Biology Section, Izmir, Türkiye; Duisburg-Essen University, Faculty of Chemistry, Department of Environmental Microbiology and Biotechnology, Essen, Germany.
Ovayurt T; Izmir Katip Çelebi University, Graduate School of Natural and Applied Sciences, Department of Biomedical Technology, Izmir, Türkiye.
Yüksel Gürüz A; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye; Ege University, Faculty of Medicine, Department of Parasitology, Izmir, Türkiye.
Ün C; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Faculty of Science, Department of Biology Molecular Biology Section, Izmir, Türkiye; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye.
Kantarci AG; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye; Ege University, Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Izmir, Türkiye.
Döskaya M; Ege University, Vaccine Development Application and Research Center, Izmir, Türkiye; Ege University, Institute of Health Sciences, Department of Vaccine Studies, Izmir, Türkiye; Ege University, Faculty of Medicine, Department of Parasitology, Izmir, Türkiye.

Vaccine ; 2024 Jun 15.

Article en En | MEDLINE | ID: mdl-38880692

ABSTRACT

ABSTRACT

Toxoplasma gondii is an obligate intracellular parasite that can infect a variety of mammals including humans and causes toxoplasmosis. Unfortunately, a protective and safe vaccine against toxoplasmosis hasn't been developed yet. In this study, we developed a DNA vaccine encoding the SRS13 protein and immunized BALB/c mice thrice with pVAX1-SRS13 through the intramuscular route (IM) or intradermally using an electroporation device (ID + EP). The immunogenicity of pVAX1-SRS13 was analyzed by ELISA, Western blot, cytokine ELISA, and flow cytometry. The protective efficacy of the pVAX1-SRS13 was investigated by challenging mice orally with T. gondii PRU strain tissue cysts. The results revealed that pVAX1-SRS13 administered through IM or ID + EP routes induced high level of anti-SRS13 IgG antibody responses (P = 0.0037 and P < 0.0001). The IFN-Î³ level elicited by the pVAX1-SRS13 (ID + EP) was significantly higher compared to the control group (P = 0.00159). In mice administered with pVAX1-SRS13 (ID + EP), CD8+ cells secreting IFN-Î³ was significantly higher compared to pVAX1-SRS13 (IM) (P = 0.0035) and the control group (P = 0.0068). Mice vaccinated with the SRS13 DNA vaccine did not induce significant IL-4 level. Moreover, a significant reduction in the number of tissue cysts and the load of T. gondii DNA was detected in brains of mice administered with pVAX1-SRS13 through ID + EP and IM routes compared to controls. In conclusion, the SRS13 DNA vaccine was found to be highly immunogenic and confers strong protection against chronic toxoplasmosis.

Palabras clave

DNA vaccine; Electroporation; SRS13; T. gondii PRU strain; Toxoplasma gondii; Toxoplasmosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google